flowchart LR NA["Catecholamines"] -->|"Adrenergic receptors"| L["Lipolysis"] NP["Natriuretic peptides"] --> L INS["Insulin"] -->|"Inhibits"| L L --> FFA["Free fatty acids + glycerol"]
4 Visceral vs Subcutaneous Fat: Metabolic and Endocrine Differences
The tissue differences seen in Chapter 3 manifest as differences in metabolism and endocrine function.
4.1 Propensity for lipolysis
The triglyceride in adipocytes is broken down when needed and released into the blood as free fatty acids (FFA) and glycerol (lipolysis). The strongest acute regulators of lipolysis in human adipocytes are catecholamines, insulin and natriuretic peptides; catecholamines act through four adrenergic receptor subtypes (in rodents the β3 receptor predominates, but not in humans) (Arner 2005).
The differences between visceral and subcutaneous fat are summarised as follows.
- Visceral adipocytes are metabolically active, prone to lipolysis and more insulin-resistant. They are more sensitive to adrenergic stimulation and have a greater capacity to generate free fatty acids (Ibrahim 2010).
- Under hormonal stimulation, visceral fat releases more fatty acids than subcutaneous fat, and this regional difference is accentuated in obesity (Arner 2005).
- Subcutaneous fat, on the other hand, is said to be more avid in taking up circulating free fatty acids and triglycerides (Ibrahim 2010).
In other words, visceral fat is a high-turnover fat that “releases easily.” Indeed, a systematic review of 61 weight-loss studies that measured visceral and abdominal subcutaneous fat by imaging found that with moderate weight loss, visceral fat was preferentially lost (a larger proportion), and this tendency weakened as the amount of weight lost increased (Chaston and Dixon 2008).
4.2 The portal hypothesis
flowchart LR V["Visceral fat<br/>(mesentery, omentum)"] -->|"Portal vein"| LV["Liver"] S["Subcutaneous fat"] -->|"Systemic circulation"| H["Whole body"] LV --> R["Contributes to dyslipidaemia,<br/>hyperinsulinaemia and<br/>impaired glucose tolerance"]
Free fatty acids produced by lipolysis in visceral fat travel via the portal vein directly to the liver. The idea that adipose tissue facing this “portal” circulation generates risk factors for cardiovascular disease and diabetes is the portal hypothesis (Björntorp 1990). Arner’s review argues that changes in visceral lipolysis directly affect the liver via the portal vein and are important for dyslipidaemia, hyperinsulinaemia and impaired glucose tolerance in obesity (Arner 2005).
In a human study using stable isotopes and hepatic vein catheterisation (68 lean and obese men and women) (Nielsen et al. 2004), it was reported that
- the proportion of free fatty acids delivered to the liver that came from visceral (splanchnic) lipolysis ranged from less than 10% to about 50%
- that proportion was higher with more visceral fat (women r = 0.49, men r = 0.52), and the slope was steeper in women
So the portal hypothesis is more accurately understood not as “visceral fat is the cause of everything,” but as “the more visceral fat increases, the greater the proportion of the liver’s exposure to visceral-derived fatty acids.”
4.3 Differences in adipokines
Adipose tissue is also an endocrine organ, and the factors secreted and their amounts differ by depot (Tchkonia et al. 2013; Lee et al. 2013).
| Adipokine | Main actions (source) | Regional differences / changes in obesity (source) |
|---|---|---|
| Adiponectin | Improves insulin resistance (mice) (Yamauchi et al. 2001); suppresses monocyte adhesion to vascular endothelium (Ouchi et al. 1999) | Low plasma levels in obese people (Arita et al. 1999). Negatively correlated with visceral fat area in 661 Japanese people (Ryo et al. 2004) |
| Leptin | Regulation of body weight and energy balance (Friedman and Halaas 1998) | In women, secretion from subcutaneous fat is 2–3 times that from omental fat. Subcutaneous fat is the main source of circulating leptin (Van Harmelen et al. 1998) |
| IL-6 | Pro-inflammatory cytokine | In obese people, release from omental fat is 2–3 times that from subcutaneous fat (Fried et al. 1998) |
| PAI-1 | Inhibits fibrinolysis (promotes thrombus formation) | Plasma PAI-1 correlates with visceral fat area but not with subcutaneous fat area (humans). In obese rats, expression increases only in visceral fat (Shimomura et al. 1996) |
| TNF-α | Involved in insulin resistance (rodents) (Hotamisligil et al. 1993) | In obesity, adipose tissue macrophages increase and inflammatory gene expression rises (Weisberg et al. 2003) |
Adiponectin was reported abroad in 1995 as Acrp30 (Scherer et al. 1995), and in 1996 a group at Osaka University independently reported it as apM1, the most abundantly expressed gene in human adipose tissue (Maeda et al. 1996). The same group reported that plasma adiponectin is paradoxically low in obese people (Arita et al. 1999) and the relationship between visceral fat and PAI-1 (Shimomura et al. 1996), and Japan’s diagnostic criteria for obesity disease emphasise visceral fat area on CT (Examination Committee of Criteria for ’Obesity Disease’ in Japan and Japan Society for the Study of Obesity 2002).
4.4 “Gluteal and femoral subcutaneous fat is protective”?
Regarding gluteal and femoral subcutaneous fat (gluteofemoral fat), the review by Manolopoulos et al. summarises the following (Manolopoulos et al. 2010).
- In population studies, a larger gluteofemoral fat mass is independently associated with favourable lipid and glucose profiles and lower cardiovascular and metabolic risk
- In day-to-day metabolism it is more “passive” than abdominal fat, and acts protectively by storing fatty acids long-term
- Leptin and adiponectin are positively, and inflammatory cytokines negatively, associated with gluteofemoral fat mass
- Loss of gluteofemoral fat, as in Cushing’s syndrome or lipodystrophy, increases metabolic and cardiovascular risk
It has also been framed that an increase in upper-body fat (visceral and abdominal subcutaneous fat) is an independent risk, whereas gluteofemoral fat mass acts protectively (Lee et al. 2013).
4.5 Summary
- Visceral fat has active lipolysis and higher insulin resistance (Ibrahim 2010; Arner 2005). It is preferentially lost with moderate weight loss (Chaston and Dixon 2008).
- Free fatty acids from visceral fat go straight to the liver via the portal vein (portal hypothesis) (Björntorp 1990). The visceral-derived share of fatty acids reaching the liver ranges from under 10% to about 50%, rising with visceral fat mass (Nielsen et al. 2004).
- Visceral fat is associated with low adiponectin, high PAI-1 and increased IL-6 release (Ryo et al. 2004; Shimomura et al. 1996; Fried et al. 1998), while leptin comes mainly from subcutaneous fat (Van Harmelen et al. 1998).
- Gluteofemoral subcutaneous fat behaves, if anything, protectively (Manolopoulos et al. 2010).